# Aryl Hydrocarbon Receptor (AhR) and Vascular Endothelial Growth Factor (VEGF) Crosstalk in Doxorubicin Nephrotoxicity: Mechanisms and Therapeutic Perspectives

**Authors:** Noha A. Alshuwayer, Qamraa H. Alqahtani, Marwa H. Hussein, Raeesa Mohammed, Iman H. Hasan

PMC · DOI: 10.3390/cimb48010116 · Current Issues in Molecular Biology · 2026-01-22

## TL;DR

This study explores how nanocurcumin may protect against kidney damage caused by doxorubicin chemotherapy by modulating VEGF and AhR pathways.

## Contribution

The novel contribution is demonstrating that nanocurcumin can counteract doxorubicin-induced nephrotoxicity via VEGF and AhR pathway modulation.

## Key findings

- Nanocurcumin pretreatment significantly improved kidney function and reduced oxidative stress in doxorubicin-treated rats.
- Nanocurcumin normalized renal pro-inflammatory mediators and preserved glomerular and tubular structures.
- Nanocurcumin reduced the overexpression of VEGF and AhR induced by doxorubicin.

## Abstract

Doxorubicin (DOX), a widely used chemotherapeutic, is constrained by its nephrotoxicity, characterized by endothelial injury, inflammation, and oxidative stress. Vascular endothelial growth factor (VEGF) signaling in the kidney serves a dual function. Under normal conditions, it supports the survival of glomerular endothelial cells and maintains vascular stability, but when excessively activated, it disrupts angiogenesis and contributes to kidney injury. In this context, we hypothesize that Nanocurcumin (CUR-NP), a nano-formulated curcumin derivative with enhanced bioavailability, can modulate the VEGF pathway and restore regular renal activity. Thus, this study aims to explore the potential protective effect of CUR-NP on DOX-induced renal injury in male rats. Thirty-two Wistar albino rats were used and distributed into four groups. CUR-NP (80 mg/kg dissolved in 1% CMC) was administered by oral gavage for two weeks. A single dose of DOX (15 mg/kg) (i.p.) was injected on day seven of the study. Results showed that DOX increased the circulating creatinine, urea, and urea-nitrogen levels, while pretreatment with CUR-NP markedly alleviated kidney function. In addition, CUR-NP treatment significantly normalized oxidative stress markers in renal tissues, such as NO, GSH, and SOD, and improved renal pro-inflammatory mediators, TNF-α, IL-6, and NF-κB-p65. DOX caused degeneration of glomeruli and tubules with degenerated epithelial lining and casts in their lumens. Conversely, CUR-NP maintained standard tubular and glomerular structure. Immunohistochemistry showed that DOX strongly upregulated VEGF and AhR, while CUR-NP markedly reduced their expression, countering VEGF/AhR pathway disruption and helping restore physiological signaling.

## Linked entities

- **Proteins:** VEGFA (vascular endothelial growth factor A), AHR (aryl hydrocarbon receptor), TNF (tumor necrosis factor), IL6 (interleukin 6), Nos1 (nitric oxide synthase 1, neuronal), LOC23687505 (pyrimidodiazepine synthase), SOD1 (superoxide dismutase 1)
- **Chemicals:** Doxorubicin (PubChem CID 31703), creatinine (PubChem CID 588), urea (PubChem CID 1176), urea-nitrogen (PubChem CID 31295)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12839651/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12839651/full.md

## References

53 references — full list in the complete paper: https://tomesphere.com/paper/PMC12839651/full.md

---
Source: https://tomesphere.com/paper/PMC12839651